Lao-Tzu Allan-Blitz

List of Publications by Year
in descending order

36 papers	311 citations	933447 10 h-index	940533 16 g-index
37 all docs	37 docs citations	37 times ranked	479 citing authors

#	Article	IF	Citations
1	Heterogeneity in SARS-CoV-2 Positivity by Ethnicity in Los Angeles. Journal of Racial and Ethnic Health Disparities, 2022, 9, 1206-1209.	3.2	5
2	Is It Ethical to Mandate SARS-CoV-2 Vaccinations among Incarcerated Persons?. American Journal of Bioethics, 2022, 22, 8-10.	0.9	2
3	Environmental and health risks posed to children by artisanal gold mining: A systematic review. SAGE Open Medicine, 2022, 10, 205031212210769.	1.8	2
4	Implementation and first experiences with a multimodal mentorship curriculum for medicine-paediatrics residents. Annals of Medicine, 2022, 54, 1313-1319.	3.8	0
5	Zebra Hunting: How Caring Is Lost When We Chase Diseases. Journal of General Internal Medicine, 2021, 36, 2816-2817.	2.6	0
6	Prevalence of Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Youth. Pediatric Infectious Disease Journal, 2021, 40, e132-e133.	2.0	3
7	The Rising Prevalence of SARS-CoV-2 Infection May Not be Due to Young Adults. Pediatric Infectious Disease Journal, 2021, 40, e213-e214.	2.0	0
8	SARS-CoV-2 Seroprevalence Data to Guide Local Public Health Interventions. JAMA Internal Medicine, 2021, 181, 1014.	5.1	0
9	Heterogenous Exposures May Drive SARS-CoV-2 Positivity Among Different Subpopulations. Open Forum Infectious Diseases, 2021, 8, ofab183.	0.9	1
10	The ongoing HIV epidemic in American youth: challenges and opportunities. MHealth, 2021, 7, 33-33.	1.6	11
11	Association of Lower Socioeconomic Status and SARS-CoV-2 Positivity in Los Angeles, California. Journal of Preventive Medicine and Public Health, 2021, 54, 161-165.	1.9	17
12	Reply: Seroprevalence of SARS-CoV-2 After the Largest Initial Epidemic Wave in the United States: Findings from New York City, May 13â€“July 21, 2020. Journal of Infectious Diseases, 2021, 224, 556-557.	4.0	5
13	A Real-World Comparison of SARS-CoV-2 Rapid Antigen Testing versus PCR Testing in Florida. Journal of Clinical Microbiology, 2021, 59, e0110721.	3.9	31
14	Characteristics of <scp>SARSâ€CoV</scp>â€2 positive individuals in California from two periods during notable decline in incident infection. Health Science Reports, 2021, 4, e384.	1.5	0
15	Improved determination of Neisseria gonorrhoeae gyrase A genotype results in clinical specimens. Journal of Antimicrobial Chemotherapy, 2019, 74, 2913-2915.	3.0	10
16	Similar, but different: drivers of the disproportionate <scp>HIV</scp> and sexually transmitted infection burden of key populations. Journal of the International AIDS Society, 2019, 22, e25344.	3.0	13
17	Using the genetic characteristics of Neisseria gonorrhoeae strains with decreased susceptibility to cefixime to develop a molecular assay to predict cefixime susceptibility. Sexual Health, 2019, 16, 488.	0.9	21
18	P639â€…Molecular markers to predict cefixime decreased susceptibility ofneisseria gonorrhoeae: a global review. , 2019, , .		0

#	Article	IF	Citations
19	P660â€…Extra-genital ciprofloxacin-resistantneisseria gonorrhoeaeinfections among sexual-health clinic users in lima, peru. , 2019, , .		0
20	PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, S113-S117.	2.1	19
21	Venue-Based HIV-Testing: An Effective Screening Strategy for High-Risk Populations in Lima, Peru. AIDS and Behavior, 2019, 23, 813-819.	2.7	16
22	Ciprofloxacin May be Efficacious in Treating Wild-Type Gyrase A Genotype Neisseria gonorrhoeae Infections. Sexually Transmitted Diseases, 2018, 45, e18-e18.	1.7	10
23	High incidence of extra-genital gonorrheal and chlamydial infections among high-risk men who have sex with men and transgender women in Peru. International Journal of STD and AIDS, 2018, 29, 568-576.	1.1	8
24	Field evaluation of a smartphone-based electronic reader of rapid dual HIV and syphilis point-of-care immunoassays. Sexually Transmitted Infections, 2018, 94, 589-593.	1.9	4
25	The development of an online risk calculator for the prediction of future syphilis among a high-risk cohort of men who have sex with men and transgender women in Lima, Peru. Sexual Health, 2018, 15, 261.	0.9	11
26	Implementation of a Rapid Genotypic Assay to Promote Targeted Ciprofloxacin Therapy of Neisseria gonorrhoeae in a Large Health System. Clinical Infectious Diseases, 2017, 64, ciw864.	5.8	51
27	High prevalence of extra-genital chlamydial or gonococcal infections among men who have sex with men and transgender women in Lima, Peru. International Journal of STD and AIDS, 2017, 28, 138-144.	1.1	18
28	Wild-Type Gyrase A Genotype of Neisseria gonorrhoeae Predicts In Vitro Susceptibility to Ciprofloxacin: A Systematic Review of the Literature and Meta-Analysis. Sexually Transmitted Diseases, 2017, 44, 261-265.	1.7	35
29	The Need for Outcome Studies Prior to Large-Scale Implementation of Screening for Anal Cancer. Clinical Infectious Diseases, 2017, 65, 179-180.	5.8	1
30	O05.6â€…The impact of a rapid genotypicneisseria gonorrhoeaeassay on targeted ciprofloxacin therapy. , 2017, , .		0
31	P1.31â€…The costs of targeted ciprofloxacin therapy vs. empiric therapy forneisseria gonorrhoeaeinfections over a thirteen-month study period. , 2017, , .		1
32	O14.2â€…High incidence of non-urethralneisseria gonorrhoeaeandchlamydia trachomatisinfections among men who have sex with men and transgender women in lima, peru. , 2017, , .		0
33	P3.128â€…Development of a risk calculator for the 3-month prediction of incident syphilis infection among high-risk men who have sex with men and transgender women presenting to a std clinic in lima, peru. , 2017, , .		0
34	Implementation of a Rapid Molecular Assay for Determination of Neisseria gonorrhoeae Susceptibility in a Large Health System. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
35	Codon 91 Gyrase A Testing Is Necessary and Sufficient to Predict Ciprofloxacin Susceptibility in Neisseria gonorrhoeae. Journal of Infectious Diseases, 2016, 215, jiw551.	4.0	5
36	Resistance-Guided Therapy for Neisseria gonorrhoeae. Clinical Infectious Diseases, 0, , .	5.8	11